Calcium Channel Blockers: Dihydropyridines, Verapamil, Diltiazem and Safety

Pharmacology education review. Updated 10 November 2026. This is not an individual prescribing protocol; follow current local guidelines and product labeling.

Overview

Calcium channel blockers (CCBs) inhibit L-type voltage-gated calcium channels and are used for hypertension, chronic angina and selected arrhythmias. Tissue selectivity distinguishes predominantly vascular dihydropyridines from non-dihydropyridines with substantial cardiac conduction effects [1,2].

Chemical and functional classes

  • Dihydropyridines (DHPs): amlodipine, nifedipine, felodipine, nicardipine and clevidipine; relax peripheral arteriolar smooth muscle.
  • Phenylalkylamine: verapamil, which slows AV-nodal conduction and reduces contractility.
  • Benzothiazepine: diltiazem, with both cardiac and vascular activity.

Phenylalkylamines are not a separate fourth major clinical class from non-dihydropyridines: verapamil itself is a phenylalkylamine. Mibefradil was withdrawn because of interactions and should not be presented as a contemporary standard option [1].

Molecular mechanism and effects

L-type calcium-channel blockade reduces intracellular calcium in vascular smooth muscle, decreasing resistance and blood pressure. In SA/AV nodal tissue, calcium entry contributes to depolarization; verapamil and diltiazem slow nodal conduction and may reduce heart rate. DHPs do not usually provide reliable AV-nodal rate control; rapid-onset short-acting nifedipine can cause reflex sympathetic activation and is not advised for unsupervised acute BP reduction [1].

Clinical indications

Amlodipine and related long-acting DHPs are common first-line antihypertensive treatments. Verapamil and diltiazem may be used for certain supraventricular tachycardias and AF rate control when LV systolic function permits. DHPs and non-DHPs can relieve chronic stable angina; CCBs are important for vasospastic angina. Intravenous nicardipine or clevidipine may be used in selected hypertensive emergencies with careful monitoring [1,2].

Pharmacokinetics and interactions

Most agents undergo hepatic metabolism and differ in half-life and formulation. Amlodipine has a long elimination half-life suited to once-daily treatment. Verapamil/diltiazem interact through CYP3A4 and P-glycoprotein, increasing exposure to selected statins or digoxin. Combining non-DHPs with beta blockers raises bradycardia/AV block risks; grapefruit interactions vary by agent [1].

Adverse effects and precautions

DHPs cause headache, flushing and dependent ankle edema. Verapamil can cause constipation, bradycardia and heart block. Non-DHPs can worsen HFrEF owing to negative inotropic effects and should generally be avoided in significant LV systolic dysfunction. Overdose may produce refractory hypotension, bradyarrhythmias and hyperglycemia requiring specialist toxicology management [1,2].

Clinical summary

Choice depends on whether vascular dilation or cardiac rate control is desired; a CCB suitable for hypertension may be contraindicated for AF rate control in reduced ejection fraction [2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for diagnosis and management of atrial fibrillation. Circulation. 2024;149:e1–e156. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11095842/
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *